OCS3 (suppressor of cytokine signaling 3) is a protein encoded by the SOCS3 gene and is induced by various cytokines, including leptin. When activated, SOCS3 binds to the phosphorylated LR (leptin receptor) through its SH2 (Src homology-2) domain and inhibits JAK (Janus kinase) tyrosine kinase activity by its N-terminal kinase inhibitory region. [1] [2] [3] [4] This effect of SOCS3 may be an important regulator of leptin signaling and could contribute to development of resistance to leptin's cardiometabolic effects. Peripheral leptin administration induces SOCS3 mRNA expression in hypothalamic regions, 5, 6 especially in the arcuate nucleus of the hypothalamus, which coexpresses LR and other neuropeptides that regulate food intake. 5 In addition, increased SOCS3 expression is associated with attenuated leptin-induced STAT3 (signal transducer and activator of transcription 3) activation in the arcuate nucleus in mice with diet-induced obesity (DIO).
S
OCS3 (suppressor of cytokine signaling 3) is a protein encoded by the SOCS3 gene and is induced by various cytokines, including leptin. When activated, SOCS3 binds to the phosphorylated LR (leptin receptor) through its SH2 (Src homology-2) domain and inhibits JAK (Janus kinase) tyrosine kinase activity by its N-terminal kinase inhibitory region. [1] [2] [3] [4] This effect of SOCS3 may be an important regulator of leptin signaling and could contribute to development of resistance to leptin's cardiometabolic effects. Peripheral leptin administration induces SOCS3 mRNA expression in hypothalamic regions, 5, 6 especially in the arcuate nucleus of the hypothalamus, which coexpresses LR and other neuropeptides that regulate food intake. 5 In addition, increased SOCS3 expression is associated with attenuated leptin-induced STAT3 (signal transducer and activator of transcription 3) activation in the arcuate nucleus in mice with diet-induced obesity (DIO). 7 Increased SOCS3 expression has been suggested to play a role in body weight dysregulation in obesity because mice with neuronal deficiency of SOCS3 were reported to be resistant to DIO. 8 Although these observations suggest that SOCS3 is important for regulating body weight, the role of SOCS3 in mediating the chronic blood pressure (BP) and glucose lowering effects of leptin are still unknown. There have been no previous studies, to our knowledge, that examined the role of central nervous system (CNS) SOCS3 signaling in mediating the chronic actions of leptin on appetite, thermogenesis, glucose homeostasis, and cardiovascular function. In addition, the potential role of neuronal SOCS3 deficiency in cardiovascular regulation and in modulating the chronic BP effects of leptin is unclear, especially in conditions in which SOCS3 may be activated, such as in DIO.
In the present study, we inactivated SOCS3 in the entire nervous system, using a genetic approach, to determine whether SOCS3 signaling is an important modulator of leptin's chronic effects on cardiovascular and metabolic functions. We also tested the hypothesis that nervous system SOCS3 deficiency protects against the adverse metabolic effects of a chronic high-fat-high-fructose diet (HFFD), including weight gain, increased adiposity, impaired glucose tolerance, and increased liver lipids, while increasing BP and heart rate (HR).
Our results indicate that nervous system SOCS3 deficiency amplifies leptin's effects to decrease plasma insulin and glucose concentrations and to increase BP. In addition, nervous system SOCS3 deficiency attenuated body weight gain, adiposity, and liver steatosis while increasing energy expenditure and HR but did not improve glucose tolerance in male or female mice fed HFFD. However, HFFD significantly increased BP to a greater extent in female mice with nervous system SOCS3 deficiency, suggesting a sex difference in the role of SOCS3 signaling on BP regulation in obesity.
Methods
The experimental procedures and protocols for these studies followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center.
The authors declare that the raw data that support the findings of this study are available from the corresponding author on reasonable request. Expanded Methods and additional data can be found in the online-only Data Supplement.
Animals
Mice were randomly divided into different groups for acute and chronic experiments. Male and female 6-to 22-week-old control SOCS3 flox/flox (n=21) and SOCS3-Nestin-Cre, (n=20) mice were used in these studies. SOCS3-Nestin-Cre mice with nervous system SOCS3 deficiency were generated by crossing Nestin-Cre mice (C57Bl 6J background) that express Cre recombinase specifically in neurons (B6Cg-Tg [Nestin-Cre]/1kln/J; Jackson Laboratories) with SOCS3 flox/flox mice (generously provided by Dr George W. Booz, University of Mississippi Medical Center). Only mice homozygous for the SOCS3 flox/flox gene that also expressed Cre recombinase were used for the group with neuronal SOCS3 deficiency (SOCS3-NestinCre mice; Figure 1A ). Littermate homozygous SOCS3 flox/flox mice from our colony were used as controls for the experiments (See the online-only Data Supplement for discussion of methods to validate SOCS3 deficiency).
Food and water were offered ad libitum throughout the experiment, and room temperature was maintained at 23 to 24°C. A normal sodium intake of ≈460 µmol/d was maintained during the leptin infusion experiments via the constant saline infusion combined with sodium-deficient rodent chow as described previously. 9 All mice were allowed to recover for 8 to 10 days after the surgery before baseline measurements were taken.
High-Fat-High-Fructose Diet
Separate groups of control male (n=6) and female (n=6) SOCS3 flox/flox mice and male (n=6) and female (n=7) SOCS3-Nestin-Cre mice were individually housed and fed an HFFD (Harlan Teklad TD-0881, 4.7 Kcal/g, 45% fat), and water was replaced by degassed 7UP (0.416 kcal/mL; Pepper/Seven Up, Inc, Plano, TX) starting at 6 weeks of age until 26 weeks of age. Consumption of an HFFD diet mimics the obesogenic Western diet, including high fructose intake from beverages, and leads to many characteristics of the metabolic syndrome, including increased body weight, increased adiposity, hyperglycemia, hyperinsulinemia, and hyperleptinemia, in rodents.
10-13

Experimental Design and Methods
Acute Leptin Injection
To determine whether nervous system SOCS3 inactivation amplifies the acute effects of leptin on appetite, food intake was measured 2, 4, 15, and 24 hours after an intraperitoneal leptin (5 mg/kg) or vehicle injection (saline, 0.3 mL) between 5:00 and 6:00 pm in separate groups of noninstrumented and nonfasted male and female 22-weekold SOCS3 flox/flox (n=7) and SOCS3-Nestin-Cre (n=6) mice fed control diet.
Chronic Leptin Infusion
After an 8-to 10-day postsurgery recovery period plus 5 days of stable baseline control measurements, leptin was added to the saline vehicle and infused at 2 µg/kg per minute in male and female SOCS3 flox/flox (n=6) and SOCS3-Nestin-Cre (n=6) mice for 7 days followed by a 5-day post-treatment period during which only saline vehicle was infused. BP and HR were measured by telemetry, 24 h/d (online-only Data Supplement), and food and water intake was recorded daily. Blood samples (100 µL) were collected via a tail snip after 6 hours of fasting (8:00 am to 2:00 pm) during the control period (day 5), on the last day of leptin infusion (day 7 of treatment) and at the end of the post-treatment period for measurements of plasma glucose, leptin, and insulin concentrations.
Oxygen Consumption and Motor Activity
In separate experiments, male and female 22-week-old SOCS3 flox/flox (n=6-12) and SOCS3-Nestin-Cre (n=6-13) mice fed the control or the HFFD were placed individually in metabolic cages (AccuScan Instruments, Inc, Columbus, OH) equipped with oxygen sensors to measure oxygen consumption (VO 2 ) and infrared beams to determine motor activity. After 4 to 6 days of acclimatization, VO 2 and animal activity were recorded for 3 consecutive control days and then during 7 days of leptin infusion (4 µg/kg per minute, IP) and a 5-day posttreatment period (online-only Data Supplement).
Oral Glucose Tolerance Test
D-glucose (3 mg/kg of lean body mass plus 1 mg/kg of fat mass) was administered by gavage after a 5-hour fast in male and female 22-week-old SOCS3 flox/flox (n=6-8) and SOCS3-Nestin-Cre (n=7-9) mice fed a control or an HFFD. Blood samples were collected by tail snip, and blood glucose was measured using glucose strips (ReliOn) at baseline, 15, 30, 60, 90, and 120 minutes after glucose administration.
Body Weight, Body Composition, and Liver Composition
Body weight was measured twice a week from 6 until 20 weeks of age, and weekly changes in body composition were analyzed using magnetic resonance imaging (4-in-1 EchoMRI-900TM; Echo Medical System, Houston, TX). Whole livers from male and female SOCS3 flox/flox (n=5) and SOCS3-Nestin-Cre (n=5) mice fed an HFFD were harvested to determine liver fat and lean mass composition using EchoMRI and Oil Red O staining (online-only Data Supplement).
We also performed Oil Red O staining in frozen liver sections of SOCS3 flox/flox (n=5) and SOCS3-Nestin-Cre (n=5) mice fed an HFFD to assess liver lipid deposits. Sections (10-µm thick) were fixed in 10% buffered formalin for 5 minutes and stained for 10 minutes with 0.5% Oil Red O in 60% isopropyl alcohol. The slides were washed several times in water and counterstained in Mayer hematoxylin for 30 seconds and mounted in aqueous mounting media.
Plasma Hormones and Glucose Measurements
Plasma leptin and insulin concentrations were measured with ELISA kits (R&D Systems and Crystal Chem, Inc, respectively), and plasma glucose concentrations were determined using the glucose oxidation method (Beckman Glucose Analyzer 2).
Statistical Analyses
Results are expressed as means±SEM. Data were analyzed by paired t test or 1-way ANOVA with repeated measures followed by Dunnett post hoc test for comparisons between control and experimental values within each group when appropriate. Comparisons between different groups were made by unpaired t test or 1-way ANOVA followed by Dunnett post hoc test when appropriate. Statistical significance was accepted at a level of P<0.05.
Results
Expression of SOCS3 in the Hypothalamus and Cortex of SOCS3 flox/flox and SOCS3-Nestin-Cre Mice
The qRT (quantitative reverse transcription) polymerase chain reaction analysis showed that expression of SOCS3 mRNA in the hypothalamus and cortex of SOCS3-Nestin-Cre was ≈70% and 62% lower, respectively, compared with control mice ( Figure 1B ).
p-STAT3 Immunofluorescence in the Hypothalamus of SOCS3 flox/flox and SOCS3-Nestin-Cre Mice After Acute Leptin Injection
After acute intraperitoneal leptin injection, p-STAT3 staining was markedly enhanced in SOCS3-Nestin-Cre compared with control mice ( Figure 1C and 1D ). Because STAT3 is the major signaling pathway for the effects of leptin to reduce food intake, increased p-STAT3 in the arcuate nucleus provides additional confirmation of the functional effects of neuronal SOCS3 deficiency in SOCS3-Nestin-Cre compared with control SOCS3 flox/flox mice.
Effect of CNS SOCS3 Deletion on Body Length, Body Weight, and Visceral Fat
Mice with neuronal SOCS3 deletion showed ≈22% reduction in food intake (2.4±0.1 versus 3.2±0.5 g) and a tendency for lower body weight (20.4±1.4 versus 25.3±2.5 g), lean mass (14.2±0.6 versus 17.1±2.7 g), and fat mass (3.1±0.6 versus 4.5±0.5 g) compared with control mice as early as 10 weeks of age, and these differences persisted until 22 weeks of age when experiments were initiated ( Figure S1 in the online-only Data Supplement). The small reductions in body weight, lean mass, and fat mass were not statistically significant. Body length (nasal to anal distance) at 22 weeks of age was shorter in male and female SOCS3-Nestin-Cre mice compared with SOCS3 flox/flox control mice (8.3±0.1 versus 9.2±0.9 cm).
Acute and Chronic Effects of Leptin on Food Intake and Body Weight
Compared with vehicle injection, acute intraperitoneal leptin injection reduced 24-hour food intake in SOCS3 flox/flox mice but caused a greater reduction in SOCS3-Nestin-Cre mice (Figure 2A) . The acute anorexic effect of leptin was observed as early as 4 hours postinjection in SOCS3-Nestin-Cre mice but only after 16 hours in SOCS3 flox/flox mice. These results indicate that SOCS3 deficiency amplifies the acute effects of leptin to reduce appetite. No changes in body weight were observed after acute leptin or saline vehicle injections (data not shown).
Chronic intravenous leptin infusion for 7 consecutive days markedly reduced food intake in SOCS3 flox/flox and SOCS3-Nestin-Cre mice ( Figure 2B ). The reduction in food intake was associated with ≈10% weight loss in both groups ( Figure 2C ). After stopping leptin infusion, food intake and body weight returned to baseline values in both groups ( Figure 2B and 2C) .
To determine whether the presence of Cre recombinase per se may induce a phenotypic response to chronic leptin infusion, we previously investigated the anorexigenic effect of leptin in Nestin-Cre mice. Chronic leptin infusion in these mice reduced food intake and body weight to the same extent observed in control SOCS3 flox/flox mice, thus indicating that the presence of Cre recombinase by itself does not alter leptin's ability to suppress appetite and to promote weight loss.
14 There were no significant sex differences in the anorexic effect of acute or chronic leptin infusion ( Figure S2 ).
Effects of Chronic Leptin Infusion on VO 2 and Motor Activity
At baseline, SOCS3-Nestin-Cre mice exhibited higher VO 2 compared with control mice ( Figure 3A) . Chronic leptin infusion increased VO 2 by ≈15% and 20% in SOCS3 flox/flox and SOCS3-Nestin-Cre mice, respectively ( Figure 3B ). At baseline, no differences in motor activity were observed between groups (SOCS3-Nestin-Cre: 87±18 versus SOCS3 flox/flox : 78±6 m/d). Chronic leptin infusion significantly reduced motor activity in both groups; however, this effect was more pronounced in SOCS3-Nestin-Cre mice (SOCS3-Nestin-Cre: 47±8 versus SOCS3 flox/flox : 60±8 m/d).
Effects of Chronic Leptin Infusion on Plasma Glucose, Insulin, and Leptin Concentrations
At baseline, SOCS3-Nestin-Cre mice showed significantly lower plasma glucose, insulin, and leptin concentrations ( Figure 3C through 3E) . Chronic intravenous leptin infusion increased plasma leptin concentrations similarly in SOCS3
flox/flox and SOCS3-Nestin-Cre mice ( Figure 3E ) to concentrations that were similar to those observed in severe obesity. Leptin infusion in SOCS3 flox/flox and SOCS3-Nestin-Cre mice reduced plasma glucose and insulin concentrations. However, leptin's effects on glucose concentration were significantly greater in SOCS3-Nestin-Cre mice ( Figure 3C and 3D). These results indicate that neuronal system SOCS3 deficiency may amplify the impact of chronic hyperleptinemia to reduce plasma insulin and glucose concentrations.
Mean Arterial Pressure and HR Responses to Chronic Leptin Infusion
Mean arterial pressure (MAP) and HR were measured 24 h/d by telemetry (online-only Data Supplement). SOCS3-NestinCre and SOCS3 flox/flox mice showed similar MAP at baseline ( Figure 4A ). Chronic leptin infusion caused a gradual and modest elevation in MAP in both groups, despite decreased food intake and weight loss which would normally be associated with reduction in MAP. The elevation in BP during leptin infusion, however, was potentiated in SOCS3-Nestin-Cre mice; on day 7 of treatment, leptin increased MAP by ≈6 mm Hg in SOCS3 flox/flox mice and ≈15 mm Hg in SOCS3-Nestin-Cre mice. These data indicate that suppression of neuronal SOCS3 exacerbates the chronic effects of leptin to increase arterial pressure. Our previous observations showed that expression of Cre recombinase in neurons did not alter the BP responses to leptin. 9, 14 SOCS3-Nestin-Cre mice also exhibited increased HR compared with SOCS3 flox/flox mice ( Figure 4A ), but there were no significant changes in HR during chronic leptin infusion ( Figure 4B ). Because there were no significant sex differences for the metabolic and cardiovascular responses to leptin, Figure 4A and 4B represent combined data from male and female mice. Figure 5A ). This reduced weight gain was associated with reduced fat mass ( Figure 5B ).
Female SOCS3-Nestin-Cre and SOCS3 flox/flox mice exhibited significant lower lean mass than their male counterparts ( Figure 5C ). Male and female SOCS3-Nestin-Cre mice also had significantly lower lean mass compared with their respective controls ( Figure 5C ). Although male SOCS3-Nestin-Cre mice were approaching the body weight and fat mass of male SOCS3 flox/flox mice at 20 weeks of age, female SOCS3-Nestin-Cre mice had progressively lower body weight than female control mice.
Mice were euthanized at 22 weeks of age and livers harvested from male and female SOCS3-Nestin-Cre mice weighed significantly less than livers from control mice. Compared with controls, male and female SOCS3-Nestin-Cre mice had significantly less liver fat accumulation as measured by EchoMRI ( Figure 5D ). These results indicate that inactivation of neuronal SOCS3 attenuates the effects of HFFD on body fat and liver fat accumulation. flox/flox mice were not significantly different at 22 weeks of age in male (3.3±0.7 versus 3.8±0.5 g) or female mice (3.1±0.6 versus 3.3±0.5 g; Figure 5E ). However, body weight was significantly lower in SOCS3-Nestin-Cre mice compared with SOCS3 flox/flox mice (male, 34±3 versus 45±3 g and female, 27±1 versus 37±2 g; Figure 5E ). There were no significant differences in glucose tolerance test at 20 weeks of age in male or female SOCS3-Nestin-Cre mice compared with control SOCS3 flox/flox mice ( Figure 5F ).
Cardiometabolic Responses to HFFD in SOCS3 flox/flox and SOCS3-Nestin-Cre Mice
Male SOCS3-Nestin-Cre mice had similar MAP (115±2 versus 116±1 mm Hg) but higher HR (657±3 versus 592±3 bpm) compared with control SOCS3 flox/flox mice fed HFFD ( Figure 6A and 6B) . In females, however, SOCS3-Nestin-Cre mice had higher MAP (121±1 versus 108±1 mm Hg) and HR Compared with control mice, SOCS3-Nestin-Cre mice had higher oxygen consumption (VO 2 ) in male (94±12 versus 69±6 mL/kg per minute) and female mice fed HFFD (97±15 versus 58±8 mL/kg per minute; Figure 6C ). There were no significant differences in blood glucose concentrations in SOCS3-Nestin-Cre compared with control mice (male, 148±8 versus 198±31 mg/dL and female, 149±12 versus 164±12 mg/dL; Figure 6D ). However, plasma insulin ( Figure 6E ) and leptin concentrations ( Figure 6F ) were significantly lower in male and female SOCS3-Nestin-Cre compared with SOCS3 flox/flox control mice at 22 weeks of age. These results indicate that nervous system SOCS3 deficiency reduces weight gain in mice fed HFFD, attenuates increased fat mass, and elevates energy expenditure but does not improve glucose tolerance during an acute glucose load in male or female mice.
Discussion
We demonstrated that nervous system SOCS3 deficiency is associated with amplified responses to leptin's effects to raise BP. In addition, neuronal SOCS3 deletion attenuated body weight gain while increasing energy expenditure and HR without altering glucose tolerance in male or female mice fed an HFFD for 14 weeks. Although nervous system SOCS3 deficiency did not improve glucose tolerance after administration of an oral glucose load in mice fed an HFFD, liver lipid accumulation and fasting plasma insulin and glucose concentrations were reduced suggesting that liver regulation of glucose metabolism was improved. We also found that on an HFFD, female SOCS3-Nestin-Cre mice exhibited significantly elevated BP compared with control mice on an HFFD, suggesting sex differences for the role of neuronal SOCS3 signaling in BP regulation in obesity.
Our results, therefore, indicate that neuronal SOCS3 signaling may play an important role in modulating the chronic actions of leptin on metabolic and cardiovascular function. Data from the present study also support our previous findings that enhanced leptin signaling may be a key link between obesity and development of hypertension. One important finding of the present study is that there were sex differences in the effect of neuronal SOCS3 deficiency on BP regulation in DIO. Although male mice with neuronal SOCS3 deficiency had similar MAP compared with male controls on an HFFD, female SOCS3-Nestin-Cre mice placed on an HFFD had elevated MAP compared with female control mice. Thus, neuronal deficiency of SOCS3 made female mice more susceptible to the hypertensive effects of an HFFD compared with males. The mechanisms for these sex differences in BP effects of neuronal SOCS3 deficiency are unclear and await further investigation. 
Role of SOCS3 in Regulating Energy Balance and Adiposity
SOCS3-Nestin-Cre mice were lighter after weaning compared with control mice of similar age and exhibited greater increases in energy expenditure in response to chronic leptin administration, suggesting that nervous system SOCS3 contributes to normal regulation of body weight.
Mori et al 8 previously showed that mice lacking SOCS3 in neurons had enhanced leptin signaling. The authors observed greater reduction in food intake and weight loss after an acute leptin injection and lesser weight gain when mice were placed on a high-fat diet. In the present study, we observed that when SOCS3-Nestin-Cre mice were fed an HFFD for 14 weeks, they exhibited attenuated weight gain and less adiposity compared with control mice. However, the reduced weight gain and adiposity of SOCS3-Nestin-Cre mice fed HFFD observed in our study may not be due entirely to reduced appetite because food intake at 22 weeks of age was similar to that found in control mice fed HFFD. On normal chow or on an HFFD, SOCS3-Nestin-Cre mice had significantly higher VO 2 compared with SOCS3 flox/flox mice on the same diets, suggesting that nervous system deficiency of SOCS3 may also increase metabolic rate. This enhanced VO 2 in mice with nervous system SOCS3 deficiency may be related to enhanced leptin signaling; previous observations indicate that leptin increases VO 2 , and we found in the present study that leptin injection increased the number and intensity of neurons positively stained for p-STAT3 in the arcuate nucleus substantially more in SOCS3-Nestin-Cre than in control mice.
Nervous system SOCS3 deficiency was also associated with reduced liver lipids in male and female mice as assessed by Oil Red O staining and EchoMRI. This large reduction in liver lipids may protect these mice against HFFD-induced hepatic insulin resistance because fasting insulin levels were markedly lower, whereas plasma glucose concentration was similar, or slightly lower, when compared with control mice. Thus, reduction in neuronal SOCS3 seems to have an important protective effect against liver steatosis in DIO, suggesting that SOCS3 signaling may exacerbate development of fatty liver and hepatic insulin resistance in obesity.
Role of SOCS3 in Glucose Homeostasis
Another important finding of the present study is that nervous system SOCS3 deficiency reduced fasting insulin and glucose levels while amplifying leptin's effects to reduce fasting plasma glucose concentration in male and female mice fed a normal diet. We previously showed that leptin administration markedly enhances peripheral tissue glucose utilization via insulin-dependent and independent mechanisms. 15, 16 Some of leptin's acute effects on tissue glucose utilization may involve local actions in peripheral tissues, but CNS actions also play an important role in leptin's chronic effects to stimulate peripheral tissue glucose utilization by mechanisms that are still unclear. [17] [18] [19] Pedroso et al 20 observed improved glucose tolerance test in mice placed on a high-fat diet with SOCS3 deficiency in LR expressing cells; this is consistent with our observation of enhanced effects of leptin to reduce fasting insulin and glucose levels in SOCS3-Nestin-Cre mice.
A surprising finding of our current study was nervous system SOCS3 deficiency did not improve glucose tolerance in male or female mice fed an HFFD, despite attenuating liver fat accumulation. Our results differ from those of Pedroso et al 20 who found improved glucose tolerance test in SOCS3-NestinCre mice fed high-fat diet. One potential explanation for this apparent discrepancy is that we used HFFD, whereas Pedroso et al used only a high-fat diet in their DIO protocol.
Although our results suggest that SOCS3 may not play a major role in the development of HFFD-induced glucose intolerance in male or female mice, neuronal SOCS3 is important in DIO-induced liver fat accumulation and development of liver insulin resistance. Further studies are needed, however, to determine the specific neurons and efferent mechanisms that link leptin with CNS SOCS3 and peripheral glucose metabolism.
Role of SOCS3 in Modulating the Chronic BP and HR Effects of Leptin
Chronic leptin infusion in rodents raises MAP and HR mainly via activation of the sympathetic nervous system. 21, 22 The stimulatory effect of leptin on sympathetic nervous system activity seems to be mediated in large part by activation of the POMC (proopiomelanocortin)-MC4R (melanocortin 4 receptor) axis. In a previous study, we showed that LR deletion specifically in POMC neurons abolished the chronic effects of leptin on MAP and HR, and acute and chronic MC4R antagonism prevent leptin-induced increases in renal sympathetic nervous system activity, arterial pressure, and HR. 9 In the present study, we found that nervous system SOCS3 deficiency exacerbated the BP response to chronic leptin infusion.
In addition, we found that female mice with nervous system SOCS3 deficiency fed an HFFD had increased BP compared with female control mice, whereas no differences were observed in male mice with nervous system SOCS3 deficiency compared with control male mice fed an HFFD. This finding suggests a sex difference for the effects of nervous system SOCS3 signaling on BP regulation in obesity caused by feeding an HFFD. Our results are consistent with prior findings of Manrique et al 23 who reported sex differences in the cardiovascular responses to an HFFD diet. However, the mechanisms by which female mice with nervous system SOCS3 deficiency are more susceptible to HFFD-induced elevations in BP are still unknown.
Previous studies by Gao et al 24 and Dhillon et al 25 showed that estrogen (E2) triggers excitatory inputs to POMC neurons and suppresses NPY (neuropeptide Y) via activation of ERα (estrogen receptor α). The effects of E2 on food intake, energy expenditure, and body weight have also been suggested to be mediated by MC4R activation. 26 Thus, one potential explanation for the finding that HFFD increased BP to a greater extent in female than male SOCS3-Nestin-cre mice fed HFFD is that E2 may contribute to activation of the POMC-MC4R axis and suppression of NPY neuron activity. However, further experiments are needed to test these potential mechanisms for sex differences in BP responses to HFFD in mice with neuronal SOCS3 deficiency. A previous study by Metlakunta et al 27 suggested that SOCS3 deficiency may increase sensitivity of the PI3K (phosphatidylinositol 3-kinase) and STAT3 pathways for acute leptin signaling in the hypothalamus. The importance of PI3K in mediating the BP effects of leptin is supported by the observation that pharmacological blockade of PI3K almost completely prevented the acute effects of leptin to increase renal sympathetic nerve activity. 28 We also showed that mice with CNS IRS2 (insulin receptor substrate 2) deficiency, which reduces PI3K signaling, are unresponsive to the chronic BP effects of leptin.
14 Thus, blockade of the inhibitory effects of SOCS3 signaling on leptin-induced activation of the IRS2/ PI3K pathway could be an important mechanism by which CNS SOCS3 deficiency amplifies leptin's effects on BP.
In summary, we demonstrated that chronic leptin infusion caused greater increases in BP in mice with nervous system SOCS3 deficiency, compared with control mice. Neuronal SOCS3 deficiency also reduced fasting insulin and glucose in mice fed a normal diet, and this was associated with reduced liver fat. Compared with controls, male and female mice with nervous system SOCS3 deficiency also had attenuated weight gain, increased energy expenditure, and decreased liver fat accumulation when fed a normal or HFFD. When female SOCS3-Nestin-Cre mice were fed an HFFD, BP increased significantly more than that in control mice fed an HFFD. Thus, nervous system SOCS3 deficiency reduces body weight and food intake and protects against liver fat accumulation and liver insulin resistance while amplifying leptin's effects on BP and exacerbating the effects of an HFFD to raise BP in females.
Perspectives
These observations provide insights into potential pathways by which leptin may differentially regulate BP, glucose homeostasis, VO 2 , and appetite. Our findings also suggest that nervous system SOCS3 deficiency may exacerbate the adverse cardiovascular effects of obesity induced by a chronic HFFD in female but not in male mice; however, the mechanisms for these sex differences remain unknown. Further studies are needed to assess the mechanisms responsible for sex differences in the role of neuronal SOCS3 signaling in metabolic and cardiovascular regulation and their role in obesityinduced cardiometabolic dysfunction.
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